A phase II clinical trial conducted in China demonstrated the efficacy and safety of savolitinib in patients with locally advanced or metastatic METex14-positive NSCLC, especially those with the pulmonary sarcomatoid carcinoma subtype (mOS = 12.5 months, 24-month OS rate = 31.5%, IRC ORR = 49.2%) [249, 250].Type II MET TKIs are also ATP-competitive but bind to MET in its inactive form, such as cabozantinib, merestinib, and glesatinib. The gene discussed is MET; the disease is non-small cell lung carcinoma.